|
|
5810 Nancy Ridge Drive, Suite 150
San Diego, CA 92121 USA
phone:858-320-8200
fax:858-320-8225
|
|
| Symbol |
Private |
| Founded |
1997 |
| Employees |
|
|
|
| www.biocept.com
|
|
|
|
 |
| Summary Description |
| Laboratory services with oncology specialization |
|
| Management |
| Bill G. Kachioff, CPA, Senior Vice President of Finance and Chief Financial Officer;
Lyle Arnold, Ph.D., Senior Vice-President of Research & Development, Chief Scientific Officer; Farideh Z. Bischoff, Ph.D., Vice-President Translational Research and Clinical Development; Philip D. Cotter, Ph.D., FACMG, Vice President and Director of Clinical Laboratories; Michael Dunn, MBA, Senior Vice President Corporate Development; Tom Burns, Vice President of Manufacturing; Kathe Houghtaling, Vice President of Human Resources; Todd G. Johnson, MBA, Vice President of Sales & Marketing; Stephen Mikolajczyk, Sr. Director of Research and Development and Principal Scientist |
| |
|
|
| |
|
| Keywords |
| oncology, circulating tumor cells |
|
|
|
| Description |
|
Biocept Laboratories is an advanced laboratory services company specializing in oncology tests, specifically for Circulating Tumor Cells (CTCs). The Company utilizes patented and innovative technologies to generate detailed reports that include results and interpretations of lab tests, thereby providing advanced prognostic and predictive assessments that guide the course of treating oncology patients. Biocept’s Cell Enrichment and Extraction (CEE™) system has been demonstrated to consistently capture extremely rare cells that may be present in only 1 of every 50-100 billion blood cells in a microfluidic device, including CTCs in patients with early-stage, metastatic, or recurrent cancers. The Company’s family of laboratory tests, the OncoCEE™ platform, provides a great deal of flexibility for both modifying the capture of rare cells as well as analyzing methods for unique requirements. Thereby, this later-stage biotechnology company is able to aid in assay development, patient population profiling, correlative science studies, the determination of patient eligibility/stratification for clinical trials, and the measurement of efficacy endpoints including surrogates such as particular biomarkers. |
|
| Technology / Differentiation |
| The Company's focus is to promote their unique technology (CEE- cell enrichment and extraction) and family of laboratory tests (OncoCEE) to high-value oncology prospects. The CEE system has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. Examples of these rare cells are circulating tumor cells (CTCs) in patients with early-stage, metastatic or recurrent cancers. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members